A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. - Wikidata - awgldk - TriplyDB

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

http://www.wikidata.org/entity/Q30442540

about

Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.Promising novel therapies for the treatment of endometrial cancer A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.Personalized therapy in endometrial cancer: challenges and opportunities.Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.Thalidomide and irradiation combination therapy increases substance P levels in vitro A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells.Personalized care in uterine cancer.Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia Systemic therapy for recurrent endometrial cancer: a review of North American trials.Current status of molecular-targeted drugs for endometrial cancer (Review).Recent Advances in Endometrial Cancer.Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer Emerging drugs in endometrial cancers.Emerging therapeutic targets in endometrial cancer.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.Endometrial cancer: redefining the molecular-targeted approach.Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings Assessment of soluble angiogenic markers in pancreatic cancer.New therapies for advanced, recurrent, and metastatic endometrial cancers.Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.Targeted therapy in gynecologic cancers: Ready for prime time?

P2860

Q27024235-66561C1B-612B-4A5B-93FC-9AECF29BE172 Q30439459-4525D7BF-CD0E-450F-894E-1F539417B377 Q33379886-BF91C1CC-3943-4205-B7A0-A61EF29FC4FA Q33386535-AAEE4546-AC4F-46C9-86BE-8CC1034367AB Q33633962-43642945-3115-4D51-B7A6-70D5CF3798CC Q33671891-FEF71BC5-7337-4BDF-8782-0AF0588D05F6 Q33742211-F1D4F251-3326-44B9-8458-1D0160507733 Q33920661-DE77F4AC-FF69-48D3-A7AA-08959976EA13 Q34781699-F605C04B-7FA2-46F8-B568-DBC52C9D2D56 Q35023418-B5FC6FAA-B33B-46FA-B4A0-FCF5BD3472DE Q35144264-F25885DD-6230-4574-829B-33D312670870 Q35180428-AE891414-C568-458A-8330-18A730543138 Q35216723-66BF52D4-AE22-4C91-B37F-D3DED19AC28B Q35248527-0942C7C0-C20B-4F6D-BD07-F8C807AE4BB4 Q35911350-5F9DC252-3E9C-4AEA-847C-7A2727B83991 Q36191443-D314E615-6FC8-4171-95B7-F8D3CC905D33 Q36206242-A6B9D4E5-C3B5-4972-989B-B6D923B489D4 Q36230673-7C10EB60-FB49-4BB9-B601-BD71CB6677C2 Q36407018-5AB41A30-7B1C-4545-9C02-27BF408B6277 Q36621362-D203D097-A194-471D-82A3-9EE7BBE896BD Q37006856-8B41DF6B-E194-42BA-88F3-3DC02D0A30AB Q37235598-E47DE015-4231-4D8A-B8E0-24C7614D6384 Q37546032-58FE0D0B-FF0E-4DEF-96E0-1BB4BB857C3E Q37560813-F1CC0447-C97A-4D40-84BE-FE14B3CF5BEA Q37620470-AE252941-EC35-42F6-A1D1-15DB33F8BE18 Q37715399-07B77345-1F96-4681-A50D-6E508A7B308C Q37786618-5CBE17FF-17BF-4064-A9BB-A1FB9101F667 Q37827340-A4F0E718-1A4D-43C1-9D41-F4A98DF19B7B Q37882459-51481CDF-DC27-4EC6-A1DB-49072E68A0BA Q38114478-FF6AD34D-9830-41E3-8E0F-DF2B884D8A44 Q38184632-4013DA9B-B28C-4062-A809-035BA19E724E Q38203354-E5B01AA1-1686-4D1E-AA4F-318A2FF2D9F0 Q38370237-62601D9E-5835-4397-94D5-B04E3C1CD338 Q38454955-E71ADCC3-F837-4EB8-B32E-7CDB5C7F16B8 Q38631272-AECE628B-3944-4028-B182-3E7007B99BF9 Q38895754-5F5527F5-51FF-4A7F-A332-75F03A44FBDB Q44623273-01B11C91-C27D-41C7-9879-3A98F9320359 Q47103210-D711AAFE-535F-433F-84F3-0624CA9027D3 Q48328979-F5829FA6-57C2-4C46-9158-C7830CA7418E Q53322899-3FBE41FC-02C5-42AC-A107-C04EF7761389

P2860

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

http://www.wikidata.org/entity/Q30442540

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

A phase II trial of thalidomid ...... ecologic Oncology Group study.

@ast

A phase II trial of thalidomid ...... ecologic Oncology Group study.

@en

type

label

A phase II trial of thalidomid ...... ecologic Oncology Group study.

@ast

A phase II trial of thalidomid ...... ecologic Oncology Group study.

@en

prefLabel

A phase II trial of thalidomid ...... ecologic Oncology Group study.

@ast

A phase II trial of thalidomid ...... ecologic Oncology Group study.

@en

P1433

Q30442540-D39267F6-1824-4617-9C0D-AB1378BEC064

P1476

Q30442540-19FACA46-7C45-4410-91F6-76B754FF9B6E

P2093

Q30442540-232BB4E6-ED41-4270-B85F-BEB7D1CF9EC9

Q30442540-80E859C0-2685-4CEB-B3F0-5F578C0C7F33

Q30442540-89C01F72-11C9-4D2A-93B8-0AB193CB8D4F

Q30442540-9836DB5F-49B5-4F05-902F-12A8A45B3C4B

Q30442540-AF06C147-B2B4-4EC6-B502-92A5164C2496

Q30442540-B7D1BA89-E2EF-427E-ABDC-E0BED260E25F

Q30442540-FB9C5D86-7520-47FD-B499-6B39E9CBFF93

P2860

Q30442540-02261179-790C-4F0C-8A17-ECD0CB813F01

Q30442540-08254AF5-272B-4729-A1C8-68D7FF2A1C99

Q30442540-0AEEE611-4A4B-412B-A1C8-252FC0F7A6E5

Q30442540-33C3A4A2-6B70-41DF-BF7E-28AE291278B0

Q30442540-36C5A7D3-BB45-4B4E-871E-81AD4F3BD2EC

Q30442540-4282939E-7B5E-4648-A9A6-1A6EA40CAE57

Q30442540-50515CEF-C8D1-419E-A10B-A4101623BD0E

Q30442540-5A374D0C-1083-435F-8056-8075E9B4BE5A

Q30442540-66CE9DAF-7894-4CA0-AE5E-1A38C184C998

Q30442540-6842F0F2-E673-4E83-80BA-FB9FBA384564

P304

Q30442540-EC8F9570-09AA-45C4-B240-EEC8DCDB87C8

P31

Q30442540-6ADB9AE2-B7CF-40EF-8D62-43FE6355FE7B

P356

Q30442540-D768E423-69F7-4457-84DE-930BC168379B

P407

Q30442540-7816D691-64C8-4484-80C9-00636D91D5AC

P433

Q30442540-0FA91D93-2961-45A0-8FC3-9D654516C2FF

P478

Q30442540-B185F2E1-10F8-457C-A6F5-774D505180DA

P50

Q30442540-902C7860-209D-41B5-BAF5-A2A12F7B6076

P577

Q30442540-1A92CC31-57C9-4149-A0C2-38CF0A5DC158

P5875

Q30442540-FF73AAC8-BAC1-43F1-AA76-1CBEF2D148F7

P698

Q30442540-EC3D74F3-90CC-45B9-BA69-ED30BFD4ED06

P921

Q30442540-1FFD7C7C-BAE2-4F85-83F6-91E7523F6DFE

Q30442540-216DF6D6-338A-463A-A5AF-687278DA5F79

Q30442540-78815569-6CF6-4DC4-A74C-65958C0593DB

P932

Q30442540-999FEF1B-3949-48BE-AA4E-2FC29A69D9E8

P356

J.YGYNO.2007.01.019

P1433

Gynecologic Oncology

P1476

A phase II trial of thalidomid ...... necologic Oncology Group study

@en

P2093

D Scott McMeekin

http://www.w3.org/2001/XMLSchema#string

Doris Benbrook

http://www.w3.org/2001/XMLSchema#string

Gynecologic Oncology Group

http://www.w3.org/2001/XMLSchema#string

Kathleen M Darcy

http://www.w3.org/2001/XMLSchema#string

Lynne Eaton

http://www.w3.org/2001/XMLSchema#string

Michael W Sill

http://www.w3.org/2001/XMLSchema#string

S Diane Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis

Cancer statistics, 2006

Angiogenesis in endometrial cancer.

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Regulation and functions of the protein C anticoagulant pathway.

Antitumor activity of thalidomide in refractory multiple myeloma.

Clinical translation of angiogenesis inhibitors.

P304

508-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2007.01.019

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Deborah J Stearns-Kurosawa

P577

2007-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6499888

http://www.w3.org/2001/XMLSchema#string

P698

17306350

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

1931832

http://www.w3.org/2001/XMLSchema#string